Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an announcement.
Australian Clinical Labs Ltd has announced an update regarding its ongoing on-market buy-back program. As of December 8, 2025, the company has repurchased a total of 2,059,874 ordinary fully paid securities, including 127,390 bought back on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:ACL) stock is a Hold with a A$3.00 price target. To see the full list of analyst forecasts on Australian Clinical Labs Ltd stock, see the AU:ACL Stock Forecast page.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Ltd operates in the healthcare industry, primarily focusing on providing pathology services. The company is known for its comprehensive range of diagnostic testing services, catering to various medical needs across Australia.
Average Trading Volume: 786,592
Technical Sentiment Signal: Buy
Current Market Cap: A$548.7M
See more insights into ACL stock on TipRanks’ Stock Analysis page.